Since first being reported in 2010, CD19-directed chimeric antigen receptor (CAR) T cells have come a long way in the treatment of B-cell lymphomas. The FDA has approved three CAR T-cell therapy products — tisagenlecleucel, axicabtagene ciloleucel, and lisocabtagene maraleucel for relapsed or refractory aggressive B-cell lymphomas . 1 The approval was based on trials that included a subset of patients with minimal comorbidities.
The FDA approval has provided an opportunity to evaluate the efficacy of these products in a real-world, non-trial setting with broader eligibility criteria. The write-up compiles the learnings from clinical and real-world studies on commercially available, FDA-approved CAR T-cell therapy products. Tisagenlecleucel A study with the largest dataset in a real-world setting showed that tisagenlecleucel achieved a high overall response , similar to pivotal trials .…
